Redeye saw a sales development that was better than our expectations. The sales development compared to last year’s quarter was up 16%, with sequential improvement. In our view, sales development is still far from the identified potential. We have primarily left our sales estimates unchanged while increasing costs as the company accelerates investments for future growth. We have decreased our Base case to SEK 6.7 (7.0) per share and our Fair value range to SEK 3.4 – 15 (3.6–15) per share.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/